BioFire Diagnostics, LLC

Belkins
With more than 25 years of molecular experience and as bioMérieux’s Global Center of Excellence for Molecular Diagnostics, BioFire sets the standard for molecular diagnostics through its pioneering advances in syndromic infectious disease testing.

Related News

EDITING TECHNOLOGY TO IDENTIFY AND ADVANCE GENETIC DYSFUNCTION THERAPIES

BlueAllele | July 27, 2020

news image

BlueAllele, a biotechnology company focused on enhancing the quality and precision of gene editing systems for patients with genetic diseases, announced the launch of PALIDON™, an innovative and proprietary repair template technology.Many rare genetic diseases are caused by mutations within a single gene. However, the location of the mutation often varies for different individuals with the same disease. Conventional gene editing approaches are primarily limited to correcting small re...

Read More

TARGOVAX PLANS CHECKPOINT COMBO TRIAL AFTER POSTING EARLY DATA ON ONCOLYTIC VIRUS

FierceBiotech | January 22, 2020

news image

Targovax has shared data from an early-phase trial that administered ONCOS-102 to mesothelioma patients. The response rate was lower in the ONCOS-102 arm than in the control cohort, but Targovax saw positives elsewhere, leading it to outline plans to pair the drug with a checkpoint inhibitor. ONCOS-102 is an adenovírus-based cancer therapy that Targovax thinks can improve on treatment options available to patients with pleural mesothelioma, a type of cancer that affects the lining of the ...

Read More

MEDICAL

TESELAGEN BIOTECHNOLOGY ANNOUNCED THE LAUNCH OF A NEW PROTEIN OPTIMIZATION TOOLKIT FOR AUTOMATED BIOTHERAPEUTIC DRUG DESIGN AND DEVELOPMENT

TeselaGen Biotechnology | May 21, 2021

news image

TeselaGen Biotechnology today announced the launch of a new protein optimization toolkit for biotherapeutic drug design and development, introducing significant enhancements to the company’s flagship TeselaGen® OS to form designing and developing pharmaceuticals and biotherapeutics faster and fewer expensive. The new capabilities, easily accessible via the cloud-based platform, simplify the planning of highly complex combinatorial protein libraries and support AI models for optimizing ...

Read More

SEXTON BIOTECHNOLOGIES PARTNERS WITH BIOSPHERIX TO CREATE A FULLY-ENCLOSED, MODULAR FILL-FINISH SYSTEM WITH RAPID DEPLOYMENT

Sexton Biotechnologies | June 11, 2020

news image

Sexton Biotechnologies has announced a new collaboration with BioSpherix Medical. As a tool and technologies partners of the Cell and Gene industry, Sexton and BioSpherix both recognize the need for cost-effective and flexible automation solutions during cell and gene therapy process development. While some upstream bioprocesses have been successfully automated, the final steps of downstream bioprocess, namely Fill-Finish, are often done manually with associated risks of contamination and user e...

Read More

BlueAllele | July 27, 2020

news image

EDITING TECHNOLOGY TO IDENTIFY AND ADVANCE GENETIC DYSFUNCTION THERAPIES

BlueAllele, a biotechnology company focused on enhancing the quality and precision of gene editing systems for patients with genetic diseases, announced the launch of PALIDON™, an innovative and proprietary repair template technology.Many rare genetic diseases are caused by mutations within a single gene. However, the location of the mutation often varies for different individuals with the same disease. Conventional gene editing approaches are primarily limited to correcting small re...

Read More

FierceBiotech | January 22, 2020

news image

TARGOVAX PLANS CHECKPOINT COMBO TRIAL AFTER POSTING EARLY DATA ON ONCOLYTIC VIRUS

Targovax has shared data from an early-phase trial that administered ONCOS-102 to mesothelioma patients. The response rate was lower in the ONCOS-102 arm than in the control cohort, but Targovax saw positives elsewhere, leading it to outline plans to pair the drug with a checkpoint inhibitor. ONCOS-102 is an adenovírus-based cancer therapy that Targovax thinks can improve on treatment options available to patients with pleural mesothelioma, a type of cancer that affects the lining of the ...

Read More

MEDICAL

TeselaGen Biotechnology | May 21, 2021

news image

TESELAGEN BIOTECHNOLOGY ANNOUNCED THE LAUNCH OF A NEW PROTEIN OPTIMIZATION TOOLKIT FOR AUTOMATED BIOTHERAPEUTIC DRUG DESIGN AND DEVELOPMENT

TeselaGen Biotechnology today announced the launch of a new protein optimization toolkit for biotherapeutic drug design and development, introducing significant enhancements to the company’s flagship TeselaGen® OS to form designing and developing pharmaceuticals and biotherapeutics faster and fewer expensive. The new capabilities, easily accessible via the cloud-based platform, simplify the planning of highly complex combinatorial protein libraries and support AI models for optimizing ...

Read More

Sexton Biotechnologies | June 11, 2020

news image

SEXTON BIOTECHNOLOGIES PARTNERS WITH BIOSPHERIX TO CREATE A FULLY-ENCLOSED, MODULAR FILL-FINISH SYSTEM WITH RAPID DEPLOYMENT

Sexton Biotechnologies has announced a new collaboration with BioSpherix Medical. As a tool and technologies partners of the Cell and Gene industry, Sexton and BioSpherix both recognize the need for cost-effective and flexible automation solutions during cell and gene therapy process development. While some upstream bioprocesses have been successfully automated, the final steps of downstream bioprocess, namely Fill-Finish, are often done manually with associated risks of contamination and user e...

Read More